TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations
Brief Summary: The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies


Options:
A: Arm Label: mepolizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mepolizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): mepolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Eosinophilic phenotype (EOS+) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS+ Benralizumab (2 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 2 mg | Arm Label: EOS+ Benralizumab (20 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 20 mg | Arm Label: EOS+ Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Arm Label: Non-eosinophil phenotype (EOS-) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS- Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: BIOLOGICAL; Name: Benralizumab 2 mg; Assigned to Arm(s): EOS+ Benralizumab (2 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 20 mg; Assigned to Arm(s): EOS+ Benralizumab (20 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): EOS+ Benralizumab (100 mg), EOS- Benralizumab (100 mg) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Eosinophilic phenotype (EOS+) Placebo, Non-eosinophil phenotype (EOS-) Placebo
C: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm A | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm B | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab Arm A; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: DRUG; Name: Benralizumab Arm B; Assigned to Arm(s): Benralizumab Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): Benralizumab 100 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Economic Assessment of an Opportunistic Screening Program for Pre-frailty State in Elderly Population.
Brief Summary: The study intervention improves functional capacity and delays frailty status in pre-frail elderly subjects.


Options:
A: Arm Label: Multidimensional intervention; Type: EXPERIMENTAL; Interventions: Other: Multidisciplinary intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multidisciplinary intervention; Assigned to Arm(s): Multidimensional intervention
B: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Multifactorial Falls Prevention Program; Type: EXPERIMENTAL; Interventions: Other: On-site exercise, Other: home-based exercise, Other: Educational and behavioural, Other: Management of modifiable risk factors | Intervention Type: OTHER; Name: On-site exercise; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: home-based exercise; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Educational and behavioural; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Management of modifiable risk factors; Assigned to Arm(s): Multifactorial Falls Prevention Program | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care
C: Intervention Type: BEHAVIORAL; Name: Falls, Fractures & Osteoporosis Risk Assessment & Management; Assigned to Arm(s): N/A
D: Arm Label: exercise with vitamin D 800 IU/d; Type: EXPERIMENTAL; Interventions: Dietary Supplement: exercise and vitamin D supplementation | Arm Label: exercise with placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: exercise and vitamin D supplementation | Arm Label: no exercise with vitamin D 800 IU/d; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: exercise and vitamin D supplementation | Arm Label: no exercise with placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: exercise and vitamin D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: exercise and vitamin D supplementation; Assigned to Arm(s): exercise with vitamin D 800 IU/d | Intervention Type: DIETARY_SUPPLEMENT; Name: exercise and vitamin D supplementation; Assigned to Arm(s): exercise with placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: exercise and vitamin D supplementation; Assigned to Arm(s): no exercise with vitamin D 800 IU/d | Intervention Type: DIETARY_SUPPLEMENT; Name: exercise and vitamin D supplementation; Assigned to Arm(s): no exercise with placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients
Brief Summary: The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adolescents with ADHD.


Options:
A: Arm Label: Methylphenidate, Dexamphetamine, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate, Drug: Placebo, Drug: Dextroamphetamine | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRC-063 25 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 25 mg | Arm Label: PRC-063 45 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 45 mg | Arm Label: PRC-063 70 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 70 mg | Arm Label: PRC-063 85 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 85 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PRC-063 25 mg and Placebo, PRC-063 45 mg and Placebo, PRC-063 70 mg and Placebo, PRC-063 85 mg and Placebo, Placebo | Intervention Type: DRUG; Name: PRC-063 25 mg; Assigned to Arm(s): PRC-063 25 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 45 mg; Assigned to Arm(s): PRC-063 45 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 70 mg; Assigned to Arm(s): PRC-063 70 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 85 mg; Assigned to Arm(s): PRC-063 85 mg and Placebo
C: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) | Arm Label: Methylphenidate (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) - Placebo | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH); Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH) - Placebo; Assigned to Arm(s): Methylphenidate (Placebo)
D: Arm Label: Lisdexamfetamine Dimesylate (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate (LDX) | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate (LDX); Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating a Novel Working Memory Training Program to Decrease Symptoms of PTSD
Brief Summary: The study is designed to evaluate the effect of a novel computer training program on PTSD.


Options:
A: Arm Label: Eye Movement Desensitization Reprocessing (EMDR); Type: EXPERIMENTAL; Interventions: Behavioral: Eye Movement Desensitization Reprocessing (EMDR) | Intervention Type: BEHAVIORAL; Name: Eye Movement Desensitization Reprocessing (EMDR); Assigned to Arm(s): Eye Movement Desensitization Reprocessing (EMDR)
B: Arm Label: High Interference Control Condition; Type: EXPERIMENTAL; Interventions: Other: Computerized Cognitive Training - active | Arm Label: Low Interference Control Condition; Type: ACTIVE_COMPARATOR; Interventions: Other: Computerized cognitive training - sham | Intervention Type: OTHER; Name: Computerized Cognitive Training - active; Assigned to Arm(s): High Interference Control Condition | Intervention Type: OTHER; Name: Computerized cognitive training - sham; Assigned to Arm(s): Low Interference Control Condition
C: Arm Label: Imaginal Exposure First, then Alcohol Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Imaginal Exposure, Behavioral: Alcohol Skills Training | Arm Label: Alcohol Skills First, then Imaginal Exposure; Type: EXPERIMENTAL; Interventions: Behavioral: Imaginal Exposure, Behavioral: Alcohol Skills Training | Arm Label: Supportive Counseling/Telehealth; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Telehealth | Arm Label: Alcohol Skills First, no additional treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Alcohol Skills Training | Arm Label: Imaginal Exposure First, no additional treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Imaginal Exposure | Intervention Type: BEHAVIORAL; Name: Imaginal Exposure; Assigned to Arm(s): Alcohol Skills First, then Imaginal Exposure, Imaginal Exposure First, no additional treatment, Imaginal Exposure First, then Alcohol Skills | Intervention Type: BEHAVIORAL; Name: Alcohol Skills Training; Assigned to Arm(s): Alcohol Skills First, no additional treatment, Alcohol Skills First, then Imaginal Exposure, Imaginal Exposure First, then Alcohol Skills | Intervention Type: BEHAVIORAL; Name: Supportive Telehealth; Assigned to Arm(s): Supportive Counseling/Telehealth
D: Arm Label: Brief Cognitive Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Cognitive Therapy | Arm Label: Assessment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief Cognitive Therapy; Assigned to Arm(s): Brief Cognitive Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients With Nonsense Mutation Cystic Fibrosis
Brief Summary: This is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ataluren (PTC124®); Type: EXPERIMENTAL; Interventions: Drug: Ataluren (PTC124®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren (PTC124®); Assigned to Arm(s): Ataluren (PTC124®) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: CPX; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sustained Aeration of Infant Lungs Trial
Brief Summary: This study is a 2-arm randomized, controlled, multi-center clinical trial to determine which of two strategies at birth are best to optimally aerate the lung of preterm infants. Specifically we will determine in 600 infants of 23-26 weeks gestational age (GA) requiring respiratory support at birth which of two lung opening strategies - either a standard PEEP/CPAP of 5-7 cm H2O in the delivery room (DR), as compared to early lung recruitment using Sustained Inflation (SI) in the DR, will result in a lower rate of the combined endpoint of death or bronchopulmonary dysplasia (BPD) at 36 weeks gestational age.

Hypotheses:

1. Early lung recruitment with SI superimposed upon standard PEEP/CPAP in the DR will reduce the need for mechanical ventilation in the first seven days of life, and reduce need for surfactant use; and
2. A policy of DR SI on standard PEEP/CPAP recruitment will confer better outcomes at 36 weeks post-menstrual age (PMA) than standard PEEP/CPAP


Options:
A: Arm Label: SI+CC; Type: EXPERIMENTAL; Interventions: Procedure: CC+SI | Arm Label: 3:1 CPR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 3:1 CPR | Intervention Type: PROCEDURE; Name: CC+SI; Assigned to Arm(s): SI+CC | Intervention Type: PROCEDURE; Name: 3:1 CPR; Assigned to Arm(s): 3:1 CPR
B: Arm Label: Intervention (CC+SI); Type: EXPERIMENTAL; Interventions: Procedure: CC+SI | Arm Label: Control (3:1 C:V); Type: ACTIVE_COMPARATOR; Interventions: Procedure: 3:1 C:V | Intervention Type: PROCEDURE; Name: CC+SI; Assigned to Arm(s): Intervention (CC+SI) | Intervention Type: PROCEDURE; Name: 3:1 C:V; Assigned to Arm(s): Control (3:1 C:V)
C: Arm Label: Control Arm-Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard of Care | Arm Label: Sustained Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Sustained Inflation | Intervention Type: PROCEDURE; Name: Sustained Inflation; Assigned to Arm(s): Sustained Intervention | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Control Arm-Standard of care
D: Arm Label: "SI group"; Type: EXPERIMENTAL; Interventions: Procedure: SI group | Arm Label: IPPV group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "IPPV group" | Intervention Type: PROCEDURE; Name: "IPPV group"; Assigned to Arm(s): IPPV group | Intervention Type: PROCEDURE; Name: SI group; Assigned to Arm(s): "SI group"

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Housing First Programs With a Social Network Substance Use Intervention
Brief Summary: Housing First programs are promising approaches to transitioning substance using chronically homeless adults to affordable housing. However, Housing First programs need to provide support to residents to adjust to their changing social environments. The proposed project fulfills a critical gap by developing an electronic tool for a social network intervention using motivational interviewing techniques as well as results of a pilot test of the tool. The hypothesis to be tested is that Housing First residents who are given the intervention will be significantly more motivated to change their drinking, drug use, sexual risk behaviors, and social networks compared to controls receiving usual care.


Options:
A: Arm Label: SBIRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SBIRT | Arm Label: SBIRT+; Type: EXPERIMENTAL; Interventions: Behavioral: SBIRT+ | Intervention Type: BEHAVIORAL; Name: SBIRT; Assigned to Arm(s): SBIRT | Intervention Type: BEHAVIORAL; Name: SBIRT+; Assigned to Arm(s): SBIRT+
B: Intervention Type: BEHAVIORAL; Name: Peer Mentoring Intervention for HCV-Infected IDUs; Assigned to Arm(s): N/A
C: Arm Label: Control Group: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Motivational Network Interview Recipients; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Network Interview | Intervention Type: BEHAVIORAL; Name: Motivational Network Interview; Assigned to Arm(s): Motivational Network Interview Recipients
D: Arm Label: NCMIT; Type: EXPERIMENTAL; Interventions: Behavioral: NCMIT | Arm Label: SCMIT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SCMIT | Intervention Type: BEHAVIORAL; Name: NCMIT; Assigned to Arm(s): NCMIT | Intervention Type: BEHAVIORAL; Name: SCMIT; Assigned to Arm(s): SCMIT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Cost-Effectiveness of a Super Simplified System for the Management of Patients With Sleep Apneas in Primary Healthcare.
Brief Summary: Primary objectives: To determine the efficacy and cost-effectiveness of a management program for patients with obstructive sleep apnea syndrome (OSAS) carried out in primary or specialist healthcare. In the primary arm, the diagnosis and therapeutic decision will be made by means of a domiciliary nasal pressure (DNP) channel and oximetry while the specialist healthcare arm will use polysomnography (PSG) in a hospital. Patients with an intermediate-high suspicion of OSAS will be included, taking as primary variables the Epworth scale, for efficacy, and the Epworth scale and EuroQol 5D, for cost-effectiveness.

Secondary objectives: efficacy of the two SAHS management programs according to the following secondary variables: a) quality-of-life tests: FOSQ questionnaire, SF36 and analogical wellbeing scale, b) adherence to and compliance with the treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): 2
B: Arm Label: Primary.; Type: EXPERIMENTAL; Interventions: Device: Diagnosis, autoCPAP, follow up. | Arm Label: Hospital; Type: ACTIVE_COMPARATOR; Interventions: Device: Diagnosis, autoCPAP, follow up. | Intervention Type: DEVICE; Name: Diagnosis, autoCPAP, follow up.; Assigned to Arm(s): Hospital, Primary.
C: Arm Label: MCI/OSA/CPAP Adherent; Type: EXPERIMENTAL; Interventions: Behavioral: CPAP adherence intervention | Arm Label: MCI/OSA/CPAP Non-adherent; Type: EXPERIMENTAL; Interventions: Behavioral: Attention control intervention | Intervention Type: BEHAVIORAL; Name: CPAP adherence intervention; Assigned to Arm(s): MCI/OSA/CPAP Adherent | Intervention Type: BEHAVIORAL; Name: Attention control intervention; Assigned to Arm(s): MCI/OSA/CPAP Non-adherent
D: Arm Label: TLC-CPAP; Type: EXPERIMENTAL; Interventions: Device: Telecommunications system | Arm Label: TLC-Control; Type: PLACEBO_COMPARATOR; Interventions: Other: TLC-Control | Intervention Type: DEVICE; Name: Telecommunications system; Assigned to Arm(s): TLC-CPAP | Intervention Type: OTHER; Name: TLC-Control; Assigned to Arm(s): TLC-Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Crossover Mucociliary Clearance Study of Aerosolized 7% NaCl Solution Administered Overnight by the tPAD Device to Subjects With Cystic Fibrosis
Brief Summary: The primary objective of this study is to determine whether a single overnight, eight-hour administration of a 7% NaCl solution delivered by the Parion Sciences transnasal Pulmonary Aerosol Delivery (tPAD) device has a significant effect on mucociliary clearance in subjects with cystic fibrosis, as compared to no treatment. This study will be conducted at the University of Pittsburgh Medical Center.


Options:
A: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline
B: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% + Hyaluronan 0.1% | Arm Label: group B; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%; Assigned to Arm(s): group A | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7%; Assigned to Arm(s): group B
C: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
D: Arm Label: HS/sham; Type: EXPERIMENTAL; Interventions: Drug: inhaled hypertonic saline (7%) | Arm Label: sham/HS; Type: EXPERIMENTAL; Interventions: Drug: inhaled hypertonic saline (7%) | Intervention Type: DRUG; Name: inhaled hypertonic saline (7%); Assigned to Arm(s): HS/sham, sham/HS

Answer: D